Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02334241
Other study ID # INR 2014-001
Secondary ID
Status Completed
Phase N/A
First received December 11, 2014
Last updated August 30, 2017
Start date October 2014
Est. completion date April 2017

Study information

Verified date August 2017
Source INRESA Pharma
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study is to demonstrate, during a 12-week follow-up, a greater efficacy of using Sorbact® dressing technology in addition to best local cares compared to best local cares alone in the management of diabetic foot ulcers


Description:

This study will select a target population of diabetic patients treated for foot ulcers of neuropathic origin, with or without arterial disease but not presenting critical limb ischaemia. No definitive wound infection should be present at inclusion. According to randomization, all present ulcers at baseline will be treated either with best local cares not including Sorbact® dressing or including systematically for all ulcers this medical device.

The main study endpoint will be a composite criterion defining a favourable limb outcome for a given patient. This criterion will be considered as present if total open wound area has decreased by 50% or more at last available evaluation whereas no definitive infection has occurred and no amputation has been required.

Patients will be followed over a maximal period of 12 weeks. At D0 (inclusion), W2, W4, W6, W8, W10 and W12 a detailed description of ulcer aspect will be done. Applied dressing will be removed according to a standardized procedure. Wound area tracing and photography of all ulcers will be performed. Off-loading system's adherence will be checked.

Between these weekly evaluations, all performed local cares will be reported and each dressing removal will be performed by using a similar procedure.


Recruitment information / eligibility

Status Completed
Enrollment 200
Est. completion date April 2017
Est. primary completion date September 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Written consent to participate obtained.

2. Male or female patient aged at least 18 years without superior limit.

3. Type 1 or 2 diabetes.

4. Less than one month HbA1c <=10%.

5. Presence, on at least one foot, of a full-thickness ulcer for at least 4 weeks (location below the malleola).

6. Neuropathy confirmed by insensitivity to monofilament (Semmes-Weinstein 5.07 monofilament according to diagnosis criteria presented in appendix 05).

7. No ulcer should present a moderate or severe infection at baseline. Concomitant treatment with systemic antibiotics at baseline is accepted if all ulcers meet none of the criteria defining moderate or severe infection.

8. All ulcers are appropriately debrided (less than 10% black tissue covering wound area on a colorimetric scale, adequate removal of hyperkeratosis).

9. All ulcers are of Grade 1 or 2 of the Wagner classification.

10. Ulcers should meet one of the following criteria:

If only one ulcer is present, its largest diameters has to be =1 cm or this ulcer is categorized as grade 2 according to Wagner classification If more than one ulcer is present, the sum of all largest diameters has to be =2 cm or one ulcer is categorized as grade 2 according to Wagner classification

11. For both legs: ABPI =0.6 and <1.3 AND ankle systolic pressure =70 mmHg or systolic toe pressure =50 mmHg or TcPo2 =30 mmHg (decubitus).

If ABPI =1.3, patent femoral artery inflow should be confirmed by digital angiography, magnetic resonance, or CT angiography or doppler ultrasonography <6 months before randomization.

12. Patient compliant to one of the accepted off-loading system.

Exclusion Criteria:

1. Previous history of major amputation (cf. § 10.3.3.2 for definition) or planned major amputation within the first month after randomization.

2. Revascularization procedure of lower leg, or any other treatment (e.g. neurostimulation) of any leg <8 weeks before randomization.

3. Patient unable to be treated with one of the accepted type of off-loading system.

4. Active Charcot foot.

5. Presence of any ulcer with evidence of skin cancer.

6. Presence of another chronic wound (i.e. present for 4 weeks or more) not involving the foot or involving the foot but extending above malleolus.

7. Patient suffering from any known active malignancy, other than basal-cell carcinoma and cervical carcinoma in situ, requiring any general, local, surgical or radiation therapy.

8. Patient suffering from severe morbid obesity (BMI =50 kg/m2).

9. Severe hypertension with systolic blood pressure =180 mm Hg or diastolic blood pressure =110 mm Hg (measured at two occasions separated by a 4 week period in a patient sitting for at least 5 min).

10. Patient with a severe comorbid disorder, not expected to survive more than 12 months

11. Acute cardiovascular events (e.g. myocardial infarction, stroke, recent coronary intervention) within 3 months before randomisation

12. Patient who are in the exclusion period following a previous participation to another trial or who are currently participating to any concomitant study with any drug or device.

13. Known intolerance to the tested medical device.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Sorbact®
Sorbact® is available in many types and sizes. These different presentations are available allowing management of quite all types of wounds of various anatomical locations, sizes or depths. Application of any of these presentations is allowed and may change during study course according to wound evolution.
Best local cares
Participating centers will provide a list of dressings they planned to use in the best local cares arm. This list must be validated by the study Steering Committee members

Locations

Country Name City State
Czechia Faculty of Medicine MU a FH St. Ann Brno Brno
Czechia Cardiologic and pediatric ambulance s.r.o. Ostrava-vitkovice
Czechia Institute for Clinical and Experimental Medicine Praha 4
Czechia Podiatrie - Ustredni vojenska nemocnice - Vojenska fakultni nemocnice Praha Praha 6
Czechia Bulovka Hospital Praha 8
France Hôpital Cardio-vasculaire Louis Pradel Bron
France CHRU LILLE Hôpital Claude Huriez Lille
France CHRU Lapeyronie Montpellier
France Hopital Civil Strasbourg
France Maison de santé protestante de Bordeaux Bagatelle Talence
Poland Gdanski Uniwersytet Medyczny Gdansk
Poland Instytut Medycny Wsi Lublin
Poland Angiodiabetica Poznan
Poland PODOS Warsaw
Poland Warszawski Uniwersytet Medyczny Warsaw

Sponsors (2)

Lead Sponsor Collaborator
INRESA Pharma RCTs

Countries where clinical trial is conducted

Czechia,  France,  Poland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Favourable healing outcome (FHO) A FHO is considered to have occurred in a given patient if all the following composite endpoints are met:
I. Total wound area (sum of areas of all present wounds on both limbs) has decreased, compared to baseline, by 50% or more at last available evaluation.
II. No minor or major amputation decided during the follow-up period. III. No moderate/severe infection of any present wound has been detected during the follow-up period.
12 weeks
Secondary Comparative evaluation of each of the items used to define a FHO. 12 weeks
Secondary Time to reach a 50% total wound area reduction. 12 weeks
Secondary Comparative evaluation of the number of complete wound closure. 12 weeks
Secondary Comparative evaluation of total absolute and relative wound area regression and of total wound edge migration (Gilman's formula; sum of the score of each individual ulcer) over 12 weeks (centralized analysis of wound area tracings). 12 weeks
Secondary Number of local cares requiring instrumental debridement (surgical or sharp debridement). 12 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT03942081 - Diabetic Foot Ulcer Imaging- Study 2 N/A
Not yet recruiting NCT06023810 - The Effect of Motivational Interviewing on Treatment Adherence, Self-Efficacy, and Satisfaction in Individuals With Diabetic Foot Ulcers N/A
Recruiting NCT02838784 - Efficacy and Safety of Artacent™ for Treatment Resistant Lower Extremity Venous and Diabetic Ulcers N/A
Terminated NCT01729286 - Health Economic Assessment of Lower Extremity Diabetic (HEALED) Ulcers With PriMatrix N/A
Completed NCT01699100 - Reduction of Plantar Pressure in Neuropathic Diabetic Foot Patients Using Insoles With Removable Pegs Design N/A
Completed NCT05908968 - Assessing the Effects of ELO Water on Diabetic Foot Ulcers N/A
Recruiting NCT05586542 - Study to Assess the Safety of DERMASEAL for Diabetic Foot Ulcers Phase 1
Completed NCT02581488 - Use of Santyl in Diabetic Foot Ulcers Phase 4
Completed NCT01956162 - Evaluation of a New Device "Orthèse Diabète" in the Healing of Foot Ulcers in Diabetic Patients N/A
Completed NCT00796744 - Safety and Efficacy Study of DSC127 in Treating Subjects With Diabetic Ulcers Phase 2
Recruiting NCT04210089 - Total Contact Soft Cast in Diabetic Foot Ulcers N/A
Completed NCT02647346 - In-Home Assessment of a Smart Foot Mat for Prevention of Diabetic Foot Ulcers N/A
Completed NCT01480362 - Treatment Study of Negative Pressure Wound Therapy for Diabetic Foot Wounds N/A
Terminated NCT01013792 - A Comparison of an Investigational Dressing to Tegaderm Matrix Wound Dressing in the Management of Diabetic Foot Ulcers N/A
Completed NCT01580917 - Dynamic Plantar Microvascular Skin Response to Compressive Loads in At-risk Diabetic and Healthy Control: a Pilot Study N/A
Completed NCT02427802 - Study of a Topical Gentamicin-Collagen Sponge Along With Systemic Antibiotic in Infected Diabetic Foot Ulcers Phase 3
Completed NCT02451722 - Evaluation of Pressure Distribution of Kyboot Shoes in Comparison to Other Foot Wear N/A
Terminated NCT01858545 - A Comparative Efficacy Study: Treatment for Non-healing Diabetic Foot Ulcers N/A
Completed NCT00516958 - Pilot Study of the Safety and Clinical Efficacy of Topical Dermacyn™ Wound Care to Treat Mild Diabetic Foot Infections Phase 2
Completed NCT03135535 - Micro-mobile Foot Compression and Diabetic Foot Phase 2